Use of maternal plasma for non-invasive prenatal diagnosis of fetal ABO genotypes.
Clin Chem Lab Med
; 45(8): 981-6, 2007.
Article
em En
| MEDLINE
| ID: mdl-17867986
ABSTRACT
BACKGROUND:
Measurement of free fetal DNA in maternal plasma opened a door for non-invasive prenatal diagnosis. Prenatal diagnosis of fetal ABO genotypes can provide a basis for the prevention and therapy of maternal-fetal incompatibility. We identified fetal ABO genotypes using fetal DNA in plasma from pregnant women with blood group O. The aim of the study was to investigate the accuracy and feasibility of this method.METHODS:
A total of 105 blood group O women in middle or late pregnancy were enrolled. Fetal DNA in maternal plasma and genomic DNA in umbilical vein blood from newborns were extracted using a QIAamp DNA Blood Kit. DNA was amplified to identify ABO genotypes by PCR with sequence-specific primers (PCR-SSP). The genotype results were evaluated using serologic tests for ABO phenotyping.RESULTS:
Using DNA from umbilical vein blood, ABO genotypes of 105 newborns were successfully identified by PCR-SSP. Using fetal DNA from maternal plasma, 88.6% (93/105) fetal ABO genotypes was correct; 12 false results were from 66 pregnant women with fetuses of type non-O. The accuracy in middle pregnancy was lower than that in late pregnancy, although the difference was not significant (0.05CONCLUSIONS: It is feasible to use measurement of fetal DNA in plasma from pregnant women with blood group O for prenatal diagnosis of fetal ABO genotypes. The method is useful for the diagnosis and therapy of ABO maternal-fetal incompatibility and hemolytic disease of the newborn.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Diagnóstico Pré-Natal
/
Sistema ABO de Grupos Sanguíneos
Tipo de estudo:
Diagnostic_studies
/
Prognostic_studies
Limite:
Female
/
Humans
/
Pregnancy
Idioma:
En
Ano de publicação:
2007
Tipo de documento:
Article